146 related articles for article (PubMed ID: 19895367)
1. Design and in vitro evaluation of novel sustained- release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers.
Hamza Yel-S; Aburahma MH
Pharm Dev Technol; 2010; 15(2):139-53. PubMed ID: 19895367
[TBL] [Abstract][Full Text] [Related]
2. Novel sustained-release fast-disintegrating multi-unit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads.
Aburahma MH; Hamza Yel-S
Pharm Dev Technol; 2011 Aug; 16(4):316-30. PubMed ID: 20307250
[TBL] [Abstract][Full Text] [Related]
3. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
Hamza Yel-S; Aburahma MH
Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
[TBL] [Abstract][Full Text] [Related]
4. Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination.
Hamza Yel-S; Aburahma MH
AAPS PharmSciTech; 2009; 10(4):1357-67. PubMed ID: 19921543
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin.
Corti G; Cirri M; Maestrelli F; Mennini N; Mura P
Eur J Pharm Biopharm; 2008 Feb; 68(2):303-9. PubMed ID: 17616379
[TBL] [Abstract][Full Text] [Related]
6. Sustained delivery of captopril from floating matrix tablets.
Jiménez-Martínez I; Quirino-Barreda T; Villafuerte-Robles L
Int J Pharm; 2008 Oct; 362(1-2):37-43. PubMed ID: 18588962
[TBL] [Abstract][Full Text] [Related]
7. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
Riis T; Bauer-Brandl A; Wagner T; Kranz H
Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.
Shoaib MH; Tazeen J; Merchant HA; Yousuf RI
Pak J Pharm Sci; 2006 Apr; 19(2):119-24. PubMed ID: 16751122
[TBL] [Abstract][Full Text] [Related]
9. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug.
Kranz H; Guthmann C; Wagner T; Lipp R; Reinhard J
Eur J Pharm Sci; 2005 Sep; 26(1):47-53. PubMed ID: 15953712
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA
Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155
[TBL] [Abstract][Full Text] [Related]
11. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
Cao QR; Choi YW; Cui JH; Lee BJ
J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
[TBL] [Abstract][Full Text] [Related]
12. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
[TBL] [Abstract][Full Text] [Related]
13. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers.
Xu X; Sun M; Zhi F; Hu Y
Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug.
Tran HT; Park JB; Hong KH; Choi HG; Han HK; Lee J; Oh KT; Lee BJ
Int J Pharm; 2011 Aug; 415(1-2):83-8. PubMed ID: 21641985
[TBL] [Abstract][Full Text] [Related]
15. Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia.
Cha KH; Park J; Cho W; Gu DG; Jeong K; Hwang SJ
Arch Pharm Res; 2009 Nov; 32(11):1593-8. PubMed ID: 20091273
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of novel metronidazole sustained release and floating matrix tablets.
Asnaashari S; Khoei NS; Zarrintan MH; Adibkia K; Javadzadeh Y
Pharm Dev Technol; 2011 Aug; 16(4):400-7. PubMed ID: 20429828
[TBL] [Abstract][Full Text] [Related]
17. Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets.
Zugasti ME; Zornoza A; Goñi Mdel M; Isasi JR; Vélaz I; Martín C; Sánchez M; Martínez-Ohárriz MC
Drug Dev Ind Pharm; 2009 Oct; 35(10):1264-70. PubMed ID: 19555243
[TBL] [Abstract][Full Text] [Related]
18. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
Tawfeek HM; Saleem IY; Roberts M
J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
[TBL] [Abstract][Full Text] [Related]
19. The influence of protonation ratio on properties of carboxymethyl starch excipient at various substitution degrees: Structural insights and drug release kinetics.
Assaad E; Mateescu MA
Int J Pharm; 2010 Jul; 394(1-2):75-84. PubMed ID: 20435114
[TBL] [Abstract][Full Text] [Related]
20. Carboxymethyl high amylose starch as excipient for controlled drug release: mechanistic study and the influence of degree of substitution.
Lemieux M; Gosselin P; Mateescu MA
Int J Pharm; 2009 Dec; 382(1-2):172-82. PubMed ID: 19716866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
